We further investigated the correlations between m6Ascore and 15 immune checkpoint-related genes in the 32 cancer types, and there was a significant correlation between PD-L1 (CD274) expression and m6Ascore in 29 cancer types (Figure S8H), which again confirmed the ability of m6Ascore to predict the clinical benefit of immunotherapy. Here, CD274 is linked to cancer.